US-based biopharmaceutical company Puma Biotechnology has reported interim five-year disease-free survival data from the Phase III ExteNET trial of PB272 (neratinib) for an adjuvant treatment of early stage, HER2-positive breast cancer.

Puma’s investigational drug PB272 acts as an irreversible tyrosine kinase inhibitor, blocking signal transduction through the epidermal growth factor receptors HER1, HER2 and HER4.

The ExteNET trial involved 2,840 patients with early stage, HER2-positive breast cancer who had undergone surgery and adjuvant treatment with trastuzumab.

After being treated with trastuzumab, patients were randomised to be administered with an extended adjuvant treatment with either neratinib or placebo for one year.

"We look forward to obtaining the full five-year DFS data, which we anticipate will be available in 2017."

The trial was primarily focused to determine the invasive disease free survival (DFS) post treatment with neratinib.

An interim five-year invasive DFS analysis has displayed a 26% reduction of risk of invasive disease recurrence or death as compared to placebo.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Puma president and CEO Alan Auerbach said: “We believe these results support the long-term clinical benefit of neratinib in the extended adjuvant treatment of patients with early stage HER2-positive breast cancer who have completed prior trastuzumab-based adjuvant therapy.

“We look forward to obtaining the full five-year DFS data, which we anticipate will be available in 2017.”

A previous two-year DFS rate for the neratinib arm of the trial was determined at 93.9% compared to placebo at 91.6%.